End Stage Renal Disease denials in California external review

In the California DMHC record, independent physician reviewers decided 23 published external-review cases involving end stage renal diseaseand overturned the plan’s denial in 65.2%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
23
2005–2021
Overturned
65.2%
15 denials reversed
Typical time to a decision
14 days
Most land between 4 and 21 days
Handled as urgent
52.2%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for dialysis after 5:00 pm. Findings: The physician reviewer found that there are potential complications that can occur during and immediately following dialysis including low blood pressure, fatigue, and prolonged bleeding, which can interfere with a patient’s ability to perform activities of daily living. In addition, many patients experience other symptoms following dialysis. As noted in the medical literature, noncompliance with dialysis has been associated with a poorer clinical outcome. A medical study dependably demonstrates substantially inferior health-related outcomes associated with missing treatments in hemodialysis patients. Moreover, mechanical difficulties with the dialysis machine itself are not infrequent, and can delay the time for dialysis to be completed.
Medical Necessity · 2019 · IMR MN19-30642
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Privigen x 2 (split dose over two days) 50 grams each day and Actemra 680 mg every four weeks. Based on the available documentation, this patient presents with biopsy proven B cell-mediated rejection status post kidney transplant in 2016 due to end-stage renal disease. Treatment has included intravenous immunoglobulin (IVIG), Actemra, tacrolimus, and belatacept. Given the ongoing concern for rejection, her provider has recommended an additional course of IVIG followed by monthly Actemra for six doses. Per Choi and colleagues, significant reducing donor specific antibodies (DSAs) has been demonstrated to improve long-term outcomes in patients with antibody-mediated rejection.
Medical Necessity · 2020 · IMR MN20-33910

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/ Case Summary: The enrollee is requesting authorization and coverage for FreeStyle Libre blood glucose 14-day reader device and FreeStyle Libre sensors. According to the medical literature, FreeStyle Libre flash glucose monitor obtained approval to function as an alternative for self-monitoring, such as finger-stick glucose monitoring. The factory-calibrated disk-like sensor is worn on the upper arm for 14 days and promotes the ease of taking multiple glucose readings per day. An enrollee may do so by passing a reader device over the sensor and obtain real-time glucose levels and trends.
Medical Necessity · 2019 · IMR MN19-31472
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for nonemergency medical transportation (NEMT) gurney transportation to and from dialysis.At issue is whether nonemergency medical transportation (NEMT) gurney transportation to and from dialysis is medically necessary. Gurney (litter) vans are transportation vehicles that can accommodate a gurney for patients who are unable to sit upright for the duration of the journey. In this case, the patient is deconditioned and has a prior history that includes stroke, atrial fibrillation, hypertension, congestive heart failure and diabetes mellitus. The patient has been hospitalized in the previous months for post-dialysis complications and possible stroke. The submitted documentation includes a home health evaluation following the patient’s most recent hospitalization.
Medical Necessity · 2020 · IMR MN20-33701

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving end stage renal disease, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for end stage renal disease? Use the California record to prepare.

Explain my denial — freeStart my appeal · $9